Insider Buying: Hikma Pharmaceuticals (LON:HIK) Insider Purchases 7,500 Shares of Stock

Posted by Shane Hupp on Aug 11th, 2026

Hikma Pharmaceuticals PLC (LON:HIK – Get Free Report) insider Tobias Hestler purchased 7,500 shares of Hikma Pharmaceuticals stock in a transaction that occurred on Monday, August 10th. The shares were acquired at an average price of GBX 1,648 per share, for a total transaction of £123,600.

Hikma Pharmaceuticals Trading Down 1.7%

HIK opened at GBX 1,621.18 on Tuesday. Hikma Pharmaceuticals PLC has a one year low of GBX 1,187 and a one year high of GBX 1,865. The company has a debt-to-equity ratio of 77.57, a current ratio of 1.98 and a quick ratio of 1.27. The business has a 50 day simple moving average of GBX 1,538.45 and a two-hundred day simple moving average of GBX 1,453.55. The firm has a market capitalization of £3.39 billion, a price-to-earnings ratio of 8.96, a PEG ratio of 2.38 and a beta of 0.66.

Wall Street Analysts Forecast Growth

Several brokerages have commented on HIK. Berenberg Bank restated a “buy” rating and issued a GBX 1,800 price objective on shares of Hikma Pharmaceuticals in a report on Tuesday, April 28th. Citigroup reiterated a “buy” rating on shares of Hikma Pharmaceuticals in a research report on Thursday, July 16th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a GBX 1,950 price target on shares of Hikma Pharmaceuticals in a research note on Friday. Finally, Jefferies Financial Group lifted their price objective on Hikma Pharmaceuticals from GBX 1,850 to GBX 1,870 and gave the company a “buy” rating in a research report on Tuesday, May 5th. Six research analysts have rated the stock with a Buy rating, According to MarketBeat.com, Hikma Pharmaceuticals has an average rating of “Buy” and a consensus target price of GBX 2,038.

Check Out Our Latest Analysis on HIK

About Hikma Pharmaceuticals

(Get Free Report)

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.